Date Time
Chairman champions prostate cancer cause during Dry July
Walking the talk is something Adjunct A/Professor Steve Callister takes seriously in his role as the National Chairman of Prostate Cancer Foundation of Australia.
The long-term prostate cancer survivor and businessman has joined PCFA’s Dry July campaign, captaining 1400 other supporters in their month-long quest to quit alcohol and raise funds for Australian men and families impacted by the disease.
His mission for Dry July is just the latest in a commitment that spans over 15 years of voluntary service to PCFA, including the last three as Chairman of the nation’s peak body.
New ‘nomogram’ opens the door to improved personalized treatments, UCLA-led study shows
UCLA
Based on the study, researchers also created an online risk calculator that forecasts the probability of overall and progression-free survival in response to LuPSMA. Denise Heady |
July 8, 2021
A new prognostic tool developed by researchers from the UCLA Jonsson Comprehensive Cancer Center and five other institutions helps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy.
The tool, described in a study published today in Lancet Oncology, analyzes a wide spectrum of imaging and clinical data and is intended to assist physicians considering treating patients with Lutetium-177 prostate-specific membrane antigen, or LuPSMA.
Tool helps predicts who will respond best to targeted prostate cancer therapy scienceblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scienceblog.com Daily Mail and Mail on Sunday newspapers.
Anti-androgen therapy for patients with advanced prostate cancer may fuel bone metastasis
Dr Bock, under the mentorship of Distinguished Professor Dietmar Hutmacher, from QUT Centre for Biomedical Technologies, has focused her research on bone metastases from breast and prostate cancers.
She developed 3D miniature bone-like tissue models in which 3D printed biomimetic scaffolds are seeded with patient-derived bone cells and tumor cells to be used as clinical and preclinical drug testing tools.
The research team investigated their hypothesis that traditional anti-androgen therapy had limited effect in the microenvironment of prostate cancer bone tumors. The team s findings are published in
Science Advances.
Anti-androgen therapy can fuel spread of bone tumours in advanced prostate cancer eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.